Transendocardial autologous bone marrow in chronic myocardial infarction using a helical needle catheter

2008 ◽  
Vol 9 (2) ◽  
pp. 111-112
Author(s):  
L de la Fuente ◽  
SH Stertzer ◽  
E Penaloza ◽  
J Argentieri ◽  
J Miano ◽  
...  
Keyword(s):  
Myocardial Infarction ◽  
Bone Marrow ◽  
Autologous Bone Marrow ◽  
Chronic Myocardial Infarction ◽  
Autologous Bone

Effect of Autologous Bone Marrow Cell Transplantation Combined with Off-Pump Coronary Artery Bypass Grafting on Cardiac Function in Patients with Chronic Myocardial Infarction

Cardiology ◽  
2014 ◽  
Vol 130 (1) ◽  
pp. 27-33 ◽  
Author(s):  
Huishan Wang ◽  
Zengwei Wang ◽  
Hui Jiang ◽  
Dongchu Ma ◽  
Weiwei Zhou ◽  
...  
Keyword(s):  
Myocardial Infarction ◽  
Bone Marrow ◽  
Coronary Artery ◽  
Cardiac Function ◽  
Artery Bypass ◽  
Autologous Bone Marrow ◽  
Chronic Myocardial Infarction ◽  
Off Pump ◽  
Autologous Bone ◽  
Pump Coronary Artery Bypass

Objectives: This study aimed to investigate the feasibility and effects of intramuscular injections of autologous bone marrow cells (BMC) combined with off-pump coronary artery bypass grafts (OPCAB) on improving cardiac function in chronic myocardial infarction patients. Methods: Ninety patients with chronic myocardial infarction were prospectively enrolled and randomized to an OPCAB with saline or an OPCAB with BMC-treatment group. After finishing CABG, patients received injections of BMC or saline into the marginal area of the infarct. The primary endpoint was incidence of emergent adverse events within 6 months. Results: There were no differences between the control and BMC-treated groups in baseline ejection fractions (EF) or wall motion score indices (WMSI) in the affected segments. At the 6-month follow-up, the ejection fraction was significantly increased in the BMC-treated group compared to controls (47.58 w 6.34 vs. 40.11 w 7.42; p < 0.05), whereas the WMSI were significantly decreased (1.25 w 0.32 vs. 1.54 w 0.53; p < 0.05), with no occurrences of life-threatening arrhythmias or death. The addition of BMC injections to OPCAB treatment increased regional perfusion to the marginal infarct area. Conclusion: These results demonstrate that BMC transplant is beneficial to the cardiac function with no adverse effects, and therefore a safe and feasible adjunct therapy providing beneficial effects in clinical practice. i 2014 S. Karger AG, Basel

Sign in / Sign up

Export Citation Format

Share Document